Popular Trials
Monoclonal Antibodies
Rituximab + Cyclosporine for Glomerulonephritis
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is testing the safety and effectiveness of combining two drugs to treat membranous nephropathy, a kidney disease associated with damage to the walls of the glomeruli. The first drug, rituximab, is an immunosuppressant that attempts to reduce the activity of the immune system. The second drug, cyclosporine, is a blood pressure lowering medication. The trial will last up to 2 years, and participants will have frequent blood and urine tests.
Alkylating agents
Combination Chemotherapy + Cyclosporine and Focal Therapy for Retinoblastoma
Recruiting1 awardPhase 2
Vancouver, British Columbia
This trial is studying a combination of chemotherapy drugs with or without cyclosporine followed by cryotherapy (freezing) and/or laser therapy in treating patients with newly diagnosed retinoblastoma in both eyes.
Popular Filters
Trials With No Placebo
Radioimmunotherapy
Astatine-211 for Acute Myeloid Leukemia
Recruiting1 awardPhase 1 & 2
Seattle, Washington
This trial gives cancer patients astatine-211, a radioactive substance, before their donor stem cell transplant. The hope is that the astatine will kill the cancer cells while having less of an effect on the healthy cells.
Anti-metabolites
Cord Blood Transplant for Leukemia
Recruiting3 awards4 criteria
Minneapolis, Minnesota
This trial is testing a new way to treat leukemia with an unrelated umbilical cord blood transplant. The transplant will use a myeloablative preparative regimen, which will include the drugs cyclophosphamide, fludarabine, and fractionated total body irradiation.
Antimetabolites
Bone Marrow Transplant for Dyskeratosis Congenita
Recruiting3 awardsPhase 2
Los Angeles, California
This trial tests a new bone marrow transplant method for patients with Dyskeratosis congenita. It uses fludarabine and antibodies to avoid harmful side effects, aiming to improve survival and reduce complications. Fludarabine-based regimens have been shown to be effective and feasible in reducing transplant-related morbidity in patients with Dyskeratosis congenita.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.